N2OFF, Inc. has announced an update to its ongoing acquisition of MitoCareX Bio Ltd. The company has amended the Securities Purchase and Exchange Agreement initially disclosed in February 2025. The amendment, dated May 18, 2025, extends the exclusivity period by an additional 90 days, allowing either party to terminate the agreement if the closing date does not occur within 180 days from the agreement's original date. This extension provides more time for N2OFF, Inc. to finalize the acquisition, which will result in MitoCareX becoming a wholly-owned subsidiary.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。